Retrospective Study of Brachytherapy
Launched by ZHEJIANG CANCER HOSPITAL · Feb 6, 2022
Trial Information
Current as of June 26, 2025
Recruiting
Keywords
ClinConnect Summary
This clinical trial is looking at the use of brachytherapy, a type of radiation treatment, for women with certain types of gynecological cancers, including cancers of the uterus, vulva, vagina, and ovaries. The study is being conducted by reviewing past cases to better understand how effective this treatment is for women aged 18 to 80 who have received brachytherapy for their cancers. The trial is currently recruiting participants.
To be eligible for this study, women must be between 18 and 80 years old and have undergone brachytherapy as part of their cancer treatment. If someone does not want to participate, that’s perfectly fine, as they will be excluded from the trial. Participants can expect to provide information about their experiences with brachytherapy and how it has impacted their health. This research aims to gather valuable insights that could help improve treatment options for future patients with gynecological cancers.
Gender
FEMALE
Eligibility criteria
- Inclusion Criteria:
- • 18 - 80 female
- • Underwent brachytherapy
- • With gynecological cancer
- Exclusion Criteria:
- • Refusal to enter this trial
About Zhejiang Cancer Hospital
Zhejiang Cancer Hospital is a leading medical institution in China, dedicated to advancing cancer research, treatment, and patient care. As a prominent clinical trial sponsor, the hospital focuses on innovative therapies and evidence-based practices to improve outcomes for cancer patients. With a multidisciplinary team of experienced oncologists and researchers, Zhejiang Cancer Hospital is committed to fostering collaboration and leveraging cutting-edge technology in its clinical trials. The institution aims to contribute significantly to the global understanding of cancer and enhance therapeutic options through rigorous research and development initiatives.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Hangzhou, Zhejiang, China
Patients applied
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Similar Trials